Miner Company
Sabra Health Care: Leveraging SHOP To Capture Silver Tsunami Tailwinds
Sabra Health Care remains a Buy, supported by strong SHOP expansion, robust guidance, and a sustainable 5.84% dividend yield. SBRA projects 4.9%-5.4% FFO growth and plans over $450 million in investments for 2026, with a solid pipeline and a good debt schedule. Leverage is steady at 5x, with recent refinancing extending maturities and reducing interest costs, supporting financial flexibility.
Tickers: SBRASILSILJSIVRSLVSLVP
Sabra Health Care remains a Buy, supported by strong SHOP expansion, robust guidance, and a sustainable 5.84% dividend yield. SBRA projects 4.9%-5.4% FFO growth and plans over $450 million in investments for 2026, with a solid pipeline and a good debt schedule. Leverage is steady at 5x, with recent refinancing extending maturities and reducing interest costs, supporting financial flexibility.